Olmesartan medoxomil/hydrochlorothiazide

Drug Profile

Olmesartan medoxomil/hydrochlorothiazide

Alternative Names: Benicar HCT; CS-866CMB; Olmetec Plus; Openvas Co; Votum Plus

Latest Information Update: 02 Nov 2016

Price : $50

At a glance

  • Originator Daiichi Sankyo Company
  • Developer Allergan; Daiichi Sankyo Company; Menarini
  • Class Antihypertensives; Benzothiadiazines; Imidazoles; Tetrazoles
  • Mechanism of Action Angiotensin type 1 receptor antagonists; Diuretics
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity No

Highest Development Phases

  • Marketed Hypertension

Most Recent Events

  • 26 Oct 2016 First generic equivalent launched in USA for Hypertension (PO)
  • 01 Jul 2014 Forest Laboratories has been acquired by Actavis Inc
  • 11 Jun 2012 Launched for Hypertension in Mexico (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top